Combining Active and Passive DNA Hypomethylation

This is a multicentre, randomized, parallel-group, placebo-controlled, double-blind phase 2 study of the efficacy and safety of oral vitamin C supplement in combination with azacitidine in patients with higher-risk MDS, CMML-2 or low-blast count AML. The primary purpose is to investigate if oral vitamin C supplementation to azacitidine, compared with azacitidine + placebo, can increase the effectiveness of epigenetic therapy in patients with higher-risk myeloid malignancies, who are not candidates for allogeneic hematopoietic stem cell transplantation.

Trial Details

NCT ID
NCT03999723
Phase
PHASE2
Sponsor
Kirsten Grønbæk
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Vitamin C
  • Placebo
Locations (sample)
  • Aalborg, Denmark|57.048,9.9187
  • Aarhus, Denmark|56.15674,10.21076
  • Copenhagen, Denmark|55.67594,12.56553
  • Copenhagen, Denmark|55.67594,12.56553
  • Odense, Denmark|55.39594,10.38831

Key Eligibility Criteria

  • Patients eligible for treatment with azacitidine with one of the following diagnoses according to World Health Organization 2016:
  • MDS Higher-risk MDS according to the IPSS-R, i.e., intermediate- to very high-risk (IPSS-R score \> 3)
  • CMML CMML with 10-29 percent marrow blasts without myeloproliferative disorder
  • AML AML with 20-30 percent blasts (low-blast count AML)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →